About the Authors
- Ola Fjellström
-
* E-mail: ola.fjellstrom@astrazeneca.com
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Sibel Akkaya
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Hans-Georg Beisel
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Per-Olof Eriksson
-
Affiliation Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Karl Erixon
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- David Gustafsson
-
Affiliation Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Ulrik Jurva
-
Affiliation Drug Metabolism and Pharmacokinetics, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Daiwu Kang
-
Affiliation Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- David Karis
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Wolfgang Knecht
-
Affiliation Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Viveca Nerme
-
Affiliation Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Ingemar Nilsson
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Thomas Olsson
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Alma Redzic
-
Affiliation Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
- Robert Roth
-
Affiliation Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Jenny Sandmark
-
Affiliation Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Anna Tigerström
-
Affiliation Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
- Linda Öster
-
Affiliation Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
Competing Interests
The authors have read the journal’s policy and have the following competing interests: All authors are, or were, employees of AstraZeneca. This does not alter adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: OF SA HGB POE KE DG UJ D. Kang D. Karis WK VN IN TO AR RR JS AT LO. Performed the experiments: SA HGB POE KE UJ D. Karis WK IN TO AR RR JS AT LO. Analyzed the data: OF SA HGB POE KE DG UJ D. Kang D. Karis WK VN IN TO AR RR JS AT LO. Contributed reagents/materials/analysis tools: SA KE D. Karis AR RR. Wrote the paper: OF HGB POE DG UJ D. Kang D. Karis WK VN IN TO JS AT.